Gastric
& Breast Cancer e-journal
DOI: 10.2122/gbc.2006.0043
COMMENTARY
|
Antharacyclin-based
chemotherapy benefits breast cancer patients with HER2 amplified
or overexpressed tumours: new trial adds on evidence towards individualized
therapy.
|
Evangelos
Briasoulis, Dimosthenis Ziogas, Michael Fatouros, Dimitrios H.
Roukos and Angelos M. Kappas |
Since
this article has no abstract we provide the first paragraph. |
Human
epidermal growth factor receptor 2 (HER2 or erbB2) is an established
molecular marker of prognosis and responsiveness to breast cancer
therapy. Randomized evidence suggests that breast cancer patients
with HER2 amplified or overexpressed can benefit from trastuzumab
therapy [1-5] |
|
|
|